Trial Profile
A phase I/II clinical trial of carbon ion radiotherapy with concurrent S-1 for operable pancreatic cancer(HIMAT1325)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Oct 2018
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Pharmacodynamics; Therapeutic Use
- 24 Oct 2018 Status changed from not yet recruiting to recruiting.
- 07 Feb 2015 New trial record